Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
-
Published:2023-01-25
Issue:3
Volume:102
Page:547-561
-
ISSN:0939-5555
-
Container-title:Annals of Hematology
-
language:en
-
Short-container-title:Ann Hematol
Author:
Niederwieser DietgerORCID, Lang Thomas, Krahl Rainer, Heinicke Thomas, Maschmeyer Georg, Al-Ali Haifa Kathrin, Schwind Sebastian, Jentzsch Madlen, Cross Michael, Kahl Christoph, Wolf Hans-Heinrich, Sayer Herbert, Schulze Antje, Dreger Peter, Hegenbart Ute, Krämer Alwin, Junghanss Christian, Mügge Lars-Olof, Hähling Detlev, Hirt Carsten, Späth Christian, Peter Norma, Opitz Bernhard, Florschütz Axel, Reifenrath Kolja, Zojer Niklas, Scholl Sebastian, Pönisch Wolfram, Heyn Simone, Vucinic Vladan, Hochhaus Andreas, Aul Carlo, Giagounidis Aristoteles, Balleisen Leopold, Oldenkott Bernd, Staib Peter, Kiehl Michael, Schütte Wolfgang, Naumann Ralph, Eimermacher Hartmut, Dörken Bernd, Sauerland Cristina, Lengfelder Eva, Hiddemann Wolfgang, Wörmann Bernhard, Müller-Tidow Carsten, Serve Hubert, Schliemann Christoph, Hehlmann Rüdiger, Berdel Wolfgang E., Pfirrmann Markus, Krug Utz, Hoffmann Verena S.
Abstract
AbstractA randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arms (n = 1154) of the AMLCG (TAD/HAM versus HAM/HAM ± G-CSF followed by TAD and maintenance) and the OSHO (intermediate-dose ara-C/mitoxantrone followed by ara-C/mitoxantrone). Median age of the 1147 eligible patients was 69 (range 60–87) years. CR/CRi status at 90 days was not significantly different between the CSA (54% (95%CI: 45–64)) and the study group arms (53% (95%CI: 47–60) and 59% (95%CI: 58–63)). The five-year event-free survival (EFS) probability (primary endpoint) was 6.2% (95%CI: 2.7–14.0) in the CSA, 7.6% (95%CI: 4.5–12.8) in study group A and 11.1% (95%CI: 9.0–13.7) in B. The 5-year OS was 17.2% (95%CI: 11.0–26.9), 17.0% (95%CI: 2.0–23.9), and 19.5% (95%CI: 16.7–22.8) in CSA, study group A and B, respectively. Neither study group differed significantly from the CSA regarding EFS, OS, or relapse-free survival. In multivariate analyses, allocation to the treatment strategy was not significantly associated with the time-to-event endpoints. The evaluation of more intensive treatment strategies did not show clinically relevant outcome differences when compared to CSA.
Funder
Universität Leipzig
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference42 articles.
1. Fitzmaurice C, Abate D, Abbasi N et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 5:1749–1768 2. Juliusson G (2011) Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 117:3473–3474 3. Juliusson G, Billström R, Gruber A et al (2006) Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 20:42–47 4. Lowenberg B, Zittoun R, Kerkhofs H et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7(9):1268–1274 5. SEER. Acute myeloid leukemia - cancer stat facts, 2021. (https://seer.cancer.gov/statfacts/html/amyl.html)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|